Business Context and Reporting Period
This Form 8-K Current Report was filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on February 21, 2025. The report addresses corporate governance changes regarding the Chief Financial Officer position. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol THAR.
Key Financial Metrics
This filing is a current report regarding executive personnel changes and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are disclosed in this document.
Material Changes
- Resignation of CFO: Thomas Hess resigned as Chief Financial Officer, effective March 26, 2025. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Appointment of New CFO: Don Kim was appointed as Chief Financial Officer, effective March 27, 2025.
- Compensatory Arrangement: A Consulting Agreement was entered into with Mr. Kim, effective February 21, 2025 (filed as Exhibit 10.1).
Outlook, Risks, and Management Commentary
Management Commentary: The Board highlighted Mr. Kim's extensive pharmaceutical industry experience. His background includes serving as CFO of UroGen Pharma Ltd. (2022–2024), VP Finance at UroGen, and roles at Strides Pharma Inc., Sun Pharma Inc., and Zoetis Inc. He is a licensed Certified Public Accountant in California.
Risks and Contingencies: The filing states there are no family relationships between Mr. Kim and other directors/officers and no transactions requiring disclosure under Item 404(a) of Regulation S-K. No other risks or contingencies are mentioned in this specific report.
Investor Verification Checklist
- Verify the transition timeline between Thomas Hess (departing March 26) and Don Kim (starting March 27) to ensure no gap in financial leadership.
- Review the attached Consulting Agreement (Exhibit 10.1) for specific compensation terms and potential severance obligations.
- Confirm Mr. Kim's prior performance and tenure at UroGen Pharma Ltd. and other listed pharmaceutical entities.
- Check subsequent filings for any interim financial reporting delays or changes in accounting practices resulting from the leadership change.